Indirect co-cultivation of HepG2 with differentiated THP-1 cells induces AHR signalling and release of pro-inflammatory cytokines.


Journal

Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 02 03 2020
revised: 27 07 2020
accepted: 27 07 2020
pubmed: 3 8 2020
medline: 24 4 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

HepG2 and THP-1 cells, the latter differentiated by phorbol 12-myristate 13-acetate (PMA), were co-cultured and characterized for typical liver-specific functions, such as xenobiotic detoxification, lipid and cholesterol metabolism. Furthermore, liver injury-associated pathways, such as inflammation, were studied. In general, the co-cultivation of these cells produced a pro-inflammatory system, as indicated by increased levels of cytokines (IL-8, TGF-α, IL-6, GM-CSF, G-CSF, TGF-β, and hFGF) in the respective supernatant. Increased expression levels of target genes of the aryl hydrocarbon receptor (AHR), e.g., CYP1A1, CYP1A2 and CYP1B1, were detected, accompanied by the increased enzyme activity of CYP1A1. Moreover, transcriptome analyses indicated a significant upregulation of cholesterol biosynthesis, which could be reduced to baseline levels by lovastatin. In contrast, total de novo lipid synthesis was reduced in co-cultured HepG2 cells. Key events of the adverse outcome pathway (AOP) for fibrosis were activated by the co-cultivation, however, no increase in the concentration of extracellular collagen was detected. This indicates, that AOP should be used with care. In summary, the indirect co-culture of HepG2/THP-1 cells results in an increased release of pro-inflammatory cytokines, an activation of the AHR pathway and an increased enzymatic CYP1A activity.

Identifiants

pubmed: 32739440
pii: S0887-2333(20)30507-5
doi: 10.1016/j.tiv.2020.104957
pii:
doi:

Substances chimiques

AHR protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0
Cytokines 0
Receptors, Aryl Hydrocarbon 0
Adenosine Triphosphate 8L70Q75FXE
Collagen 9007-34-5
Cytochrome P-450 Enzyme System 9035-51-2
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104957

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Florian Padberg (F)

German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn Strasse 8-10, 10589 Berlin, Germany; Department of Biology, Chemistry, Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany. Electronic address: florian.padberg@bfr.bund.de.

Henrik Hering (H)

German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn Strasse 8-10, 10589 Berlin, Germany.

Andreas Luch (A)

German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn Strasse 8-10, 10589 Berlin, Germany; Department of Biology, Chemistry, Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.

Sebastian Zellmer (S)

German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn Strasse 8-10, 10589 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH